Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan; Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan; One Health Research Center, Hokkaido University, Sapporo, Japan; Graduate School of Medicine, Hokkaido University, Sapporo, Japan; School of Medicine, Hokkaido University, Sapporo, Japan; Institute for the Advancement of Higher Education, Hokkaido University, Sapporo, Japan.
Division of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Cell Host Microbe. 2024 Feb 14;32(2):170-180.e12. doi: 10.1016/j.chom.2024.01.001. Epub 2024 Jan 26.
In late 2023, several SARS-CoV-2 XBB descendants, notably EG.5.1, were predominant worldwide. However, a distinct SARS-CoV-2 lineage, the BA.2.86 variant, also emerged. BA.2.86 is phylogenetically distinct from other Omicron sublineages, accumulating over 30 amino acid mutations in its spike protein. Here, we examined the virological characteristics of the BA.2.86 variant. Our epidemic dynamics modeling suggested that the relative reproduction number of BA.2.86 is significantly higher than that of EG.5.1. Additionally, four clinically available antivirals were effective against BA.2.86. Although the fusogenicity of BA.2.86 spike is similar to that of the parental BA.2 spike, the intrinsic pathogenicity of BA.2.86 in hamsters was significantly lower than that of BA.2. Since the growth kinetics of BA.2.86 are significantly lower than those of BA.2 both in vitro and in vivo, the attenuated pathogenicity of BA.2.86 is likely due to its decreased replication capacity. These findings uncover the features of BA.2.86, providing insights for control and treatment.
2023 年末,几种 SARS-CoV-2 XBB 后代,尤其是 EG.5.1,在全球范围内占主导地位。然而,一种独特的 SARS-CoV-2 谱系,即 BA.2.86 变体,也出现了。BA.2.86 在系统发育上与其他奥密克戎亚谱系不同,其刺突蛋白积累了超过 30 个氨基酸突变。在这里,我们研究了 BA.2.86 变体的病毒学特征。我们的传染病动力学模型表明,BA.2.86 的相对繁殖数明显高于 EG.5.1。此外,四种临床可用的抗病毒药物对 BA.2.86 有效。尽管 BA.2.86 的融合性与亲本 BA.2 的刺突蛋白相似,但 BA.2.86 在仓鼠中的内在致病性明显低于 BA.2。由于 BA.2.86 的生长动力学无论是在体外还是体内都明显低于 BA.2,因此 BA.2.86 的致病性减弱可能是由于其复制能力降低所致。这些发现揭示了 BA.2.86 的特征,为控制和治疗提供了依据。